Received Jun 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
received a shot October 22nd, 2023, and then the next shot was not until January 12th 2025; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose on 22-OCT-2023). On 12-JAN-2025, the patient received the 2nd dose of Shingrix. On 12-JAN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: received a shot October 22nd, 2023, and then the next shot was not until January 12th 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 01-APR-2025 The patient who received a shot in OCT 2023 and then the next shot was not until 12th JAN 2025 and because of the gap there was a recommendation by a pharmacist to get a 3rd dose. However her insurance was blocking that, so they were calling to see if it was medically necessary for her to receive that other one. The vaccine administration facility was the same as primary reporter. No other information was provided. The patient received 2nd dose of Shingrix later than recommendation, which led to lengthening of vaccine schedule.